COMPARE · Data as of August 27, 2026
ANIP vs LLY
Verdict: Side-by-side breakdown using the Bull Rankings model. ANIP scored 80.0, LLY scored 70.4 — ANIP leads.
Compare another set
ANIP
ANI Pharmaceuticals, Inc.
80
$74.01 · $1.7B
fundamentals as of
Score gap
9.6
ANIP leads
LLY
Eli Lilly and Company
70.4
$1,176.10 · $1.0T
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- CheapestANIP16.1x
- Fastest growthLLY+49.6%
- Strongest balance sheetANIP1.05
- Highest qualityLLY73 / 100
- Largest discount to fair valueANIP-47%
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
ANIP
stronger →← stronger
LLY
66
Qualityreturns · margins · balance sheet
73
94
Growthrevenue & earnings expansion
97
82
Valuevaluation vs sector peers
49
LLY is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
ANIP
LLY
$173mC
FCF
$13.6bA-
+30.9%A
Rev
+49.6%A
1.05C
D/E
1.62C
16.1xA-
P/E
40.0xC+
1.22B
PEG
1.55C+
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
ANIP
LLY
47% below
Price vs fair valuelower is cheaper
99% above
~-7%/yr
Growth the price implies10-yr FCF · lower = less priced in
~32%/yr
+65%
1-yr DCF upside
-62%
+88%
5-yr DCF upside
-50%
+128%
10-yr DCF upside
-22%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
ANIP
No notable signals flagged.
LLY
Why this score
- Raising its dividend
The companies
ANIPANI Pharmaceuticals, Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $1.7b. Down 26% from 52-week high of $99.50 — deep drawdown territory. Revenue growing +31% — in hypergrowth territory. 8 sell-side analysts rate this a Buy with a mean 1-yr target of $108.38 (implying +46% upside).
Moat
ROE 18% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 160% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
LLYEli Lilly and Company
Why now
Drug Manufacturers - General · market cap $1.0T. 9% off the 52-week high of $1292.65. Revenue growing +50% — in hypergrowth territory. 29 sell-side analysts rate this a Buy with a mean 1-yr target of $1,315 (implying +12% upside).
Moat
Net margin 34% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 79% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. $1.0T market cap places it among the largest companies in the sector — distribution, R&D, and customer-acquisition costs amortize across a base peers can't replicate.
Risk
Trailing P/E 40x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. P/S 13.2x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where ANIP and LLY diverge
On the headline score the gap is 9.6 points in favor of ANIP. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
- ValueANIP 82.5 · LLY 49.3ANIP +33.2
- QualityANIP 66.2 · LLY 73.1LLY +6.9
- GrowthANIP 93.8 · LLY 97.0LLY +3.2
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.